New candidate vaccines to prevent tuberculosis: preclinical assessment of efficacy, safety and mechanism of protection

预防结核病的新候选疫苗：功效、安全性和保护机制的临床前评估

• 批准号: nhmrc : 1043519
• 负责人: A/Pr James Triccas
• 金额: $ 39.62万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-candidate-vaccines-mechanism-protection/111584
• 关键词: New; candidate; vaccines; prevent; tuberculosis

Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.

每年有近200万人死于结核病。目前的疫苗BCG在控制结核病方面是无效的，并且对预防这种疾病所需的免疫反应类型知之甚少。我们已经发现了结核病细菌的新抗原，我们将把它们与我们的创新疫苗技术联合收割机结合起来，开发控制结核病的新疫苗。我们还将尝试了解BCG无效的原因，并利用这些信息进一步改善结核病疫苗接种。